Angiotensin Receptor–Neprilysin Inhibition in Acute Myocardial Infarction

In a randomized trial, 5661 patients with acute myocardial infarction and a reduced left ventricular ejection fraction, pulmonary congestion, or both were assigned to receive either sacubitril–valsartan or ramipril. At a median of 22 months, there was no significant difference between the two groups...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2021-11, Vol.385 (20), p.1845-1855
Hauptverfasser:	Pfeffer, Marc A, Claggett, Brian, Lewis, Eldrin F, Granger, Christopher B, Køber, Lars, Maggioni, Aldo P, Mann, Douglas L, McMurray, John J.V, Rouleau, Jean-Lucien, Solomon, Scott D, Steg, Philippe G, Berwanger, Otavio, Cikes, Maja, De Pasquale, Carmine G, East, Cara, Fernandez, Alberto, Jering, Karola, Landmesser, Ulf, Mehran, Roxana, Merkely, Béla, Vaghaiwalla Mody, Freny, Petrie, Mark C, Petrov, Ivo, Schou, Morten, Senni, Michele, Sim, David, van der Meer, Peter, Lefkowitz, Martin, Zhou, Yinong, Gong, Jianjian, Braunwald, Eugene
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events Aged Aminobutyrates - adverse effects Aminobutyrates - therapeutic use Angioplasty Angiotensin Angiotensin Receptor Antagonists - adverse effects Angiotensin Receptor Antagonists - therapeutic use Angiotensin-Converting Enzyme Inhibitors - adverse effects Angiotensin-Converting Enzyme Inhibitors - therapeutic use Biphenyl Compounds - adverse effects Biphenyl Compounds - therapeutic use Cardiology Cardiovascular Diseases - mortality Clinical trials Congestive heart failure Coronary Disease COVID-19 Death Double-Blind Method Drug Combinations Drug dosages Ejection fraction Female Heart attacks Heart Failure Heart Failure - prevention & control Hospitalization Hospitalization - statistics & numerical data Humans Hypotension - chemically induced Male Middle Aged Myocardial Infarction Myocardial Infarction - complications Myocardial Infarction - drug therapy Myocardial Infarction - mortality Neprilysin Patient safety Patients Proportional Hazards Models Ramipril - adverse effects Ramipril - therapeutic use Statistical analysis Stroke Volume Valsartan - adverse effects Valsartan - therapeutic use Ventricle Ventricular Dysfunction, Left - etiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In a randomized trial, 5661 patients with acute myocardial infarction and a reduced left ventricular ejection fraction, pulmonary congestion, or both were assigned to receive either sacubitril–valsartan or ramipril. At a median of 22 months, there was no significant difference between the two groups in the incidence of death from cardiovascular causes or incident heart failure.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2104508